Morgan Joseph Suggests Buying Shares of Gilead Sciences (GILD) on Any Weakness
More News related to GILD
- Gilead Sciences to Present at the NASDAQ OMX 23rd Investor Program
- Gilead Sciences (GILD) and Glaxo (GSK) Agree to Commercialize Viread Hep B Treatment in Five Asian Countries
- Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries
- 2010 IR Global Rankings: Invitation for Investors and Analysts Vote for Companies with the Best IR Program and for the Best IR Officer
- Gilead Sciences to Present at the Lazard Capital Markets 6TH Annual Healthcare Conference on Tuesday, November 17
Morgan Joseph reiterates a 'Buy' rating on Gilead Sciences (Nasdaq: GILD), price target $57.
Morgan analyst says, "Despite the beat-and-raise quarter, Gilead's stock was weak after hours because raised guidance was within expectations and the Street was expecting a more comprehensive revenue beat. We believe the hidden surprise in the quarter is lower-than-expected R&D expenses. Gilead's results and guidance suggest the Street is underestimating the company's margins following the integration of CV Therapeutics. Additionally, following underperformance in the market rally that ensued since March, we believe large-cap biotechnology stocks will likely outperform due to improved relative valuations, especially with better clarity on health care legislation over the next few months."
To see more analyst ratings on GILD Click Here.
Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life-threatening infectious diseases.
Related Categories
Analyst CommentsStocks Mentioned
-0.42Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
